evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract,articles/10/pmid,articles/10/title,articles/10/journal,articles/10/pubDate,articles/10/volume,articles/10/issue,articles/10/pages,articles/10/authors,articles/10/elocationId,articles/10/link,articles/10/reference,articles/10/abstract,articles/11/pmid,articles/11/title,articles/11/journal,articles/11/pubDate,articles/11/volume,articles/11/issue,articles/11/pages,articles/11/authors,articles/11/elocationId,articles/11/link,articles/11/reference,articles/11/abstract,articles/12/pmid,articles/12/title,articles/12/journal,articles/12/pubDate,articles/12/volume,articles/12/issue,articles/12/pages,articles/12/authors,articles/12/elocationId,articles/12/link,articles/12/reference,articles/12/abstract
2519,GENE_BACKGROUND,,"Smoothened (SMO) is a conserved signal transducer of the hedgehog signaling pathway, playing important roles in normal embryonic and neuronal development as well as tumorigenesis (PMID: 23719536, 21614026, 26912893). SMO is a seven-transmembrane domain protein bearing some structural and functional similarity to G-protein coupled receptors (PMID: 23636324). SMO activity is normally inhibited by patched (PTCH1), an upstream component of the Hedgehog pathway, via poorly understood mechanisms (PMID: 23719536). Binding of extracellular Hedgehog ligands to PTCH1 leads to consecutive activation of SMO, which in turn induces modifications of the downstream GLI transcription factors leading to their activation. Activating mutations in SMO lead to constitutive activation of GLI-mediated transcription of important oncogenic genes. Such mutations have been implicated in sporadic basal cell carcinoma (PMID: 9422511, 26950094) and medulloblastoma (PMID: 21614026) and have been identified in many other tumor types. Recent efforts have been made to specifically target SMO (PMID: 26781311, 26931153, 26919418, 26843616, 26527777). A distinct set of mutations in the ligand binding pocket of SMO, however, has been described to confer resistance to SMO inhibitors such as vismodegib and related cyclopamine drugs (PMID: 25759014, 26960983).",,2017-04-19,,6608,SMO,"smoothened, frizzled class receptor",True,ENST00000249373,NM_005631.4,Gx,FZD11,SMOH,False,26843616,In vitro and in vivo inhibition of breast cancer cell growth by targeting the Hedgehog/GLI pathway with SMO (GDC-0449) or GLI (GANT-61) inhibitors.,Oncotarget,2018-02-23T20:16:00,7,8,9250-70,Benvenuto M et al,doi: 10.18632/oncotarget.7062,,0001-02-23,,21614026,The Hedgehog's tale: developing strategies for targeting cancer.,Nature reviews. Cancer,2018-05-26T20:11:00,11,7,493-501,Ng JM et al,doi: 10.1038/nrc3079,,2018-05-26T05:01:00,,23636324,Structure of the human smoothened receptor bound to an antitumour agent.,Nature,2018-05-16T20:13:00,497,7449,338-43,Wang C et al,doi: 10.1038/nature12167,,0001-05-16,,25759014,Vismodegib resistance in basal cell carcinoma: not a smooth fit.,Cancer cell,2018-03-09T20:15:00,27,3,315-6,Ridky TW et al,doi: 10.1016/j.ccell.2015.02.009,,0001-03-09,,9422511,Activating Smoothened mutations in sporadic basal-cell carcinoma.,Nature,0001-01-01,391,6662,1990-02-01,Xie J et al,,,0001-01-01,,26950094,Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.,Nature genetics,2018-04-01T20:16:00,48,4,398-406,Bonilla X et al,doi: 10.1038/ng.3525,,2018-04-01T04:06:00,,26527777,"Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2017-12-20T20:15:00,33,36,4284-92,Catenacci DV et al,doi: 10.1200/JCO.2015.62.8719,,0001-12-20,,26931153,Novel small molecules targeting ciliary transport of Smoothened and oncogenic Hedgehog pathway activation.,Scientific reports,2018-03-02T20:16:00,6,,22540,Jung B et al,doi: 10.1038/srep22540,,0001-03-02,,26960983,"MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma.",Molecular cancer therapeutics,2018-06-01T20:16:00,15,6,1177-89,Filocamo G et al,doi: 10.1158/1535-7163.MCT-15-0371,,0001-06-01,,26912893,Neurons diversify astrocytes in the adult brain through sonic hedgehog signaling.,"Science (New York, N.Y.)",2018-02-19T20:16:00,351,6275,849-54,Farmer WT et al,doi: 10.1126/science.aab3103,,0001-02-19,,26781311,Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.,Cancer chemotherapy and pharmacology,2018-03-01T20:16:00,77,3,495-505,Arnhold V et al,doi: 10.1007/s00280-016-2962-5,,2018-03-01T05:05:00,,23719536,The mechanisms of Hedgehog signalling and its roles in development and disease.,Nature reviews. Molecular cell biology,2018-07-01T20:13:00,14,7,416-29,Briscoe J et al,doi: 10.1038/nrm3598,,0001-07-01,,26919418,Hedgehog Pathway Inhibition.,Cell,2018-02-25T20:16:00,164,5,831,Sekulic A et al,doi: 10.1016/j.cell.2016.02.021,,0001-02-25,
2518,GENE_SUMMARY,,"SMO, a G-protein coupled receptor, is mutated in various cancers including basal cell carcinoma and medulloblastoma.",,2017-04-19,,6608,SMO,"smoothened, frizzled class receptor",True,ENST00000249373,NM_005631.4,Gx,FZD11,SMOH,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
